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Copyright © 200? JCBN Summary Sustained virologic response with peg-interferon and ribavirin combination therapy
for 48 weeks is still inadequate. Our study examined whether short-term administration of
retinol clinically influences the anti-viral activity of interferon early during interferon and
ribavirin combination therapy. The control group received 6 MIU of interferon α-2b every day
for two weeks and then 3 times a week for 22 weeks intramuscularly plus 600 mg or 800 mg
per day of ribavirin orally for 24 weeks. The retinol group, in addition to above treatment,
received retinol 30,000 units per day orally for 3 weeks from one week before the start of
interferon α-2b plus ribavirin combination therapy. The hepatitis C virus (HCV) RNA negativity
rate at 1 week after the end of interferon α-2b and ribavirin combination therapy was 46.7%
(28/60) for the retinol group and 31.7% (19/60) for the control group, which was significantly
higher for the retinol group. The level of serum HCV RNA in the retinol group was signifi-
cantly lower at 1 week after beginning treatment as compared to the control group (p<0.01).
Furthermore, serum 2,5'AS protein at 1 week after beginning treatment was significantly
higher in the retinol group (p = 0.0002). The results suggest that retinol supplement increases
the antiviral effect of interferon α-2b plus ribavirin only during the administration of IFN α-
2b, ribavirin and retinol in patients with chronic hepatitis C.
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Introduction
Higher sustained virologic response is achieved with inter-
feron (IFN) and ribavirin combination therapy compared
to IFN monotherapy in patients with chronic hepatitis C.
However, the effect of peg-interferon (PEG-IFN) and
ribavirin combination therapy for 48 weeks, the most effec-
tive treatment for chronic hepatitis C currently available, is
still inadequate [1–6].
Viral load and hepatitis C virus (HCV) genotype are
commonly known as factors predictive of antiviral treatmentRetinol Supplement and Interferon Treatment
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outcome in patients with chronic hepatitis C [7–9]. In
addition, our group proposed that increased IFN receptors
in the liver enhance the effect of IFN treatment of chronic
hepatitis C. The manifestation of IFN-receptors on hepato-
cytes and lymphocytes influences the effect of IFN treat-
ment [10].
Retinoic acid is a derivative of vitamin A. All-trans-
retinoic acid (ATRA) is common and there are some optical
isomers such as 9-cis retinoic acid. Retinoic acid binding to
retinoic acid receptor (RAR) and retinol X receptor (RXR)
leads to some transcription activities [10–12]. Our group
previously reported that some retinoic acids raise IFN
activity via increasing IFN receptors on hepatoma cells in
vitro [13]. However, no study to date has examined clinically
the effect of retinoic acids on IFN treatment. Our study was
conducted to determine whether short-term administration
of retinol clinically influences the anti-viral activity of IFN
early during IFN plus ribavirin combination therapy.
Materials and Methods
Patients and treatment regimen
The ethical review board of the hospital approved this
study design. One-hundred and twenty adult patients with
chronic hepatitis C (60 patients/group) who gave informed
consent and who met the inclusion criteria were enrolled.
Excluded from the study were: immunocompromised or
human immunodeficiency virus-positive patients, patients
with severe psychiatric disease, patients with poorly con-
trolled diabetes mellitus or hypertension, pregnant patients,
patients with liver cirrhosis, hypersensitivity to IFN or
ribavirin, poorly controlled heart diseases, renal failure or
with creatinine clearance of less than 50 ml/min, past history
of cerebrovascular attack, patients with hepatoma or other
malignancies, and HBs antigen-positive patients.
The control group received 6 MIU of IFN α-2b by
intramuscular injection every day for two weeks and then 3
times a week for 22 weeks plus ribavirin at the dose of
600 mg (for patients weighing <60 kg) or 800 mg (for
patients weighing ≥60 kg) per day orally for 24 weeks. The
retinol group, in addition to above treatment, received
vitamin A (Chocora A®, Eisai Co. Ltd., Tokyo, Japan)
30,000 units per day orally for three weeks (from one week
before to two weeks after the start of IFN α-2b plus ribavirin
combination therapy).
Determination of serum HCV RNA and HCV genotype
Blood samples were obtained from all patients at baseline,
3 days, one week, 2 weeks after the start of combination
therapy for measurement to be conducted by a central labo-
ratory. Serum HCV RNA levels were determined by Cobas
Amplicor HCV Monitor test, version 2 (Amplicor M: Roche
Diagnostics, Tokyo, Japan). HCV genotype at baseline was
determined using a commercially available probe which can
distinguish HCV genotype 1a, 1b, 2a, 2b, and 3a (Monitor
genotype: Roche Diagnostics).
Determination of serum retinol, 2,5'-oligoadenylate syn-
thetase and ribavirin concentration
Serum retinol concentration was determined by high-
speed liquid chromatography (HPLC 800 series, Wako
Junyaku Co., Ltd., Kyoto, Japan). Serum 2,5'-oligoadenylate
synthetase (2,5'AS) protein was measured using a radio-
immunoassay kit (Eiken Chemical Co., Tokyo, Japan).
Serum ribavirin concentration was determined by HPLC
(Hitachi L-7000, Hitachi Ltd., Tokyo, Japan).
Ultrasound-guided liver biopsy
Ultrasound-guided liver biopsy was conducted using
Majima needles in 115 patients within 2 weeks before the
start of IFN α-2b plus ribavirin combination therapy. Two
patients in the retinol group and 3 patients in the control
group did not agree to have a liver biopsy. Liver specimens
were assessed histologically using Knodell’s score after
hematoxylin-eosin and Azan staining.
Statistical analysis
Data are expressed as the mean and standard error.
Statistical significance between groups was assessed with
1-way analysis of variance, Mann Whitney-U test and χ-
square test.
Results
Baseline characteristics
The retinol group and control group consisted of 60
patients each. There was no significant difference between
the groups in age, sex, body weight, alanine aminotrans-
ferase (ALT), platelet count, WBC count, hemoglobin level,
HCV RNA level, HCV genotype, Knodell score, or ribavirin
dose. Demographic characteristics in both groups are shown
in Table 1.
Serum retinol concentration during retinol administration
Serum retinol concentration was increased 1, 2, and 4
weeks after the start of IFN and ribavirin combination
therapy compared with baseline, and a significant difference
was observed after 1, 2 and 4 weeks (Fig. 1).
Time-dependent changes in serum HCV-RNA levels during
retinol administration
In both the retinol and control groups, serum HCV-RNA
was decreased. However, the HCV-RNA viral load in the
retinol group was lower than that in the control group at all
time points. At 1 week after the start of combination therapy,
the serum HCV-RNA level in the retinol group was signifi-N. Kohge et al.
J. Clin. Biochem. Nutr.
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cantly lower than that in the control group (p<0.01) (Fig. 2).
HCV RNA negativity rate at time points during retinol
administration
In the retinol group, HCV RNA negativity rate was 28.3%
(17/60) 3 days after the start of IFN α-2b plus ribavirin
combination therapy, 46.7% (28/60) after 1 week, and
60.0% (36/60) after 2 weeks. In the control group, HCV
RNA negativity rate was 16.6% (10/60) 3 days after the
start of IFN α-2b plus ribavirin combination therapy, 31.7%
(19/60) after 1 week, and 48.3% (36/60) after 2 weeks. At
one week after the start of combination therapy, the HCV
RNA negativity rate in the retinol group was significantly
higher than that in the control group (p<0.01). The HCV
RNA negativity rate in the retinol group tended to be higher
than in the control group up to two weeks of combination
therapy. This tendency was not observed at 4 weeks after the
start of combination therapy (Table 2).
Serum 2,5'AS protein one week after IFN α-2b plus ribavirin
combination therapy
Serum 2,5'AS protein one week after IFN α-2b plus
ribavirin combination therapy was higher in the retinol
group at 346 ± 31 pMol/mL than in the control group at
201 ± 21 pMol/ml (p = 0.0002, Fig. 2).
Serum ribavirin concentration one weeks after IFN α-2b
plus ribavirin combination therapy
Serum ribavirin concentration at one weeks after the start
of IFN α-2b plus ribavirin combination therapy was
2397 ± 105 ng/ml in the retinol group and 2343 ± 105 ng/ml
in control group (mean ± SE). There was no significant
Table 1. Baseline characteristics
Data are expressed as the mean ± SD.
Retinol group 
(n = 60)
Control group 
(n = 60)
p value
Age (yr) 55.1 ± 10.3 55.5 ± 10.3 0.65
Males (%) 36 (60) 40 (67) 0.45
Body weight (kg) 60.6 ± 13.3 59.6 ± 8.3 0.49
ALT (IU/l) 80.7 ± 46.2 125.0 ± 117.7 0.05
Platelet (×104/μl) 15.2 ± 5.3 15.9 ± 4.7 0.94
WBC (/μl) 4863 ± 1541 5252 ± 1343 0.14
Hemoglobin(g/dｌ) 14.1 ± 1.1 14.3 ± 1.3 0.26
HCV-RNA (KIU/ml) 529 ± 334 519 ± 273 0.86
HCV genotype 2a 30 27 0.73
2b 3 2
1b 27 31
Fibrosing score (F-factor) 1.4 ± 1.2 1.7 ± 1.0 0.14
Ribavirin dose (mg/kg) 11.6 ± 1.7 11.8 ± 1.80 0.55
Fig. 1. Serum retinol concentration before and 1, 2, and 4
weeks after the start of retinol administration. Open
circle shows serum concentration with control group,
and closed circle shows that with retinol group. *p<0.05,
**p = 0.002.
Fig. 2. Changes in serum HCV-RNA levels. Closed circles
showed HCV-RNA levels in the retinol group and open
circles those in the control group. Data are expressed as
the mean ± standard error (SE). **p<0.01; Mann-Whit-
ney U test.Retinol Supplement and Interferon Treatment
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difference between the groups in serum ribavirin concentra-
tion at 2 weeks after the start of IFN α-2b plus ribavirin
combination therapy.
Outcome
Sustained virological response (SVR), defined as HCV
RNA undetectable at 24 weeks after the end treatment, was
observed in 26 patients in the retinol group and 27 patients
in the control group. Relapse, defined as HCV RNA
undetectable at the end of treatment but detectable at 24
weeks after the end of treatment, was observed in 26 patients
in the retinol group and 23 patients in the control group. No
response, defined as HCV RNA detectable during treatment
and at 24 weeks after the end of treatment, was observed in
one patient in the retinol group and in 7 patients in the
control group. Seven patients in the retinol group and 4
patients in the control group discontinued treatment. The
dose of ribavirin was reduced in 12 patients in the retinol
group and in 15 patients in the control group. There was no
significant difference between groups in adverse reactions.
The cause of treatment discontinuation was depression in
5 patients, insulin-dependent diabetes mellitus in 2 patients,
meningitis, bleeding of the ocular fundus, leukocytopenia,
and idiopathic thrombocytopenia in one patient each.
Discussion
We have demonstrated clinically for the first time that
retinoic acids increase the antiviral effect of IFN in patients
with chronic hepatitis C. Our study showed a difference
between the retinol and control groups not only in serum
HCV RNA but also in serum 2,5'AS during vitamin A
administration. There was no difference between the groups
in serum ribavirin concentrations. Retinoids are a group of
vitamin A-related compounds that influence proliferation of
and induce differentiation in epithelial tissue and cells of the
immune system [11, 12, 14]. Hamamoto et al. [13] reported
that retinoic acids can enhance the anti-HCV replication
effect of IFN-α through up-regulation of type I IFN recep-
tors in a hepatoma cell-line. They showed that retinoic acids
enhanced IFN-induced 2,5'AS augmentation. Our study did
not directly prove the up-regulation of IFN receptors in
hepatocytes in patients with chronic hepatitis C during the
administration of retinol. However, retinol-enhanced anti-
HCV  replication accompanied with increased 2,5'AS was
observed. Our clinical results therefore reflects Hamamoto’s
study results. The double stranded RNA activated protein
kinase (PKR) as well as 2-5 AS was initially discovered as
an enzyme regulating protein synthesis in interferon-related
cells, and play a critical role in the interferon-induced viral
response [15]. Besides its antiviral effect, PKR is implicated
in cell proliferation, transcriptional regulation, tumor suppres-
sion, and apoptosis. These actions are thought to be similar
to those of retinol [16–19].
Unfortunately, anti-HCV effect of vitamin A in our study
was transient and was not associated with increased
sustained virological response. Recently, vitamin A is often
being administered long-term to patients with liver cirrhosis
and in patients at high risk of hepatocarcinogenesis to pre-
vent the development of hepatocellular carcinoma [20, 21].
However, the subjects in our study had chronic hepatitis C,
not liver cirrhosis, and the aim was not to prevent hepato-
carcinogenesis. Vitamin A accumulates, and safety of long-
term use is not established. Some chronic side effects of
carotenoids have been reported, such as liver fibrosis with
activated Ito-cell hyperplasia, hepatomegaly, musculoskeletal
symptoms, and hydrocephalus [22–26]. On the other hand,
Table 2. HCV RNA negativity rate at time points during retinol administration
*p<0.01
Rate of HCV-RNA disappearance from peripheral blood after start of treatment (%)
3 days 1 week 2 weeks
Retinol group (n = 60) 17 (28.3) 28 (46.7) 36 (60.0)
Control group (n = 60) 10 (16.6) 19 (31.7) 29 (48.3)
*
Fig. 3. Serum 2,5'AS protein concentration one week after
IFN α-2b plus ribavirin combination therapy. Data are
expressed as mean ± standard error (SE).N. Kohge et al.
J. Clin. Biochem. Nutr.
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even in the presence of normal β-carotene serum levels,
patients with cirrhosis have extremely low hepatic levels
and β-carotene supplementation may be justified [27, 28].
Patients with chronic hepatitis have mildly low hepatic
levels of β-carotene [29]. If accumulation due to long-term
administration of retinol exceeds the slight deficiency in
hepatic  β-carotene, adverse reactions due to retinol may
occur. Retinol was therefore administered short-term in the
induction stage of IFN α-2b plus ribavirin combination
therapy.
Retinol reaches the liver and is converted to retinoic acid
by hepatocytes [30]. Retinoic acid induces cellular gene
expression via nuclear receptors, which acts as transcrip-
tional factors [31]. Retinoic acid receptor (RAR) and
retinoid X receptor (RXR) are the specific receptors for
retinoic acids. These receptors bind to the cis-acting
response element composed of direct repeats of the target
gene. IFN receptor AR1 and AR2 gene sequence contains
putative retinoic acid binding sequence in the promotor
region. It is thought that these sequences may act as retinoic
acid binding sites to promote transcription of type I IFN
receptor genes [32, 33].
The dose of retinoic acid was 60 mg/m2 and 40 mg per
day in patients with acute premyelocytic leukemia and
psoriasis, respectively [34–36]. On the other hand, the dose
of retinol administered in our study was equivalent to 3 mg/
day retinoic acid. This dose is less than the conventional
clinical dose. However, the putative concentration of retinoic
acid in bodily fluids is 2 × 10−6 M if a dose of retinol equiv-
alent to 3 mg/day retinoic acid is administered [13]. This
concentration is more than the concentration of retinoic acid
which increased the anti-HCV replication effect of IFN-α
through up-regulation of type I IFN receptors in a hepatoma
cell-line.
Muto et al. [37] reported that one-year administration of
the acyclic retinoid polyretinoic acid, the molecular target of
which is RXR, prevented second primary tumors in patients
with hepatocellular carcinoma. In addition, some reports
recently suggested that 5-fluorouracil (5-FU) and interferon
combination therapy is effective in patients with advanced
hepatocellular carcinoma complicated with portal thrombi
[38–40]. The addition of retinol to 5-FU plus IFN combina-
tion treatment may improve the prognosis of advanced
hepatocellular carcinoma.
We had concern that retinol may increase not only anti-
HCV replication effect but the adverse reactions of IFN α-
2b. No significant difference was observed, however,
between the retinol and control groups in the frequency of
dose reduction or treatment interruption during IFN α-2b
plus ribavirin combination therapy. However, further study
is necessary in the future to determine whether retinol has
an effect on the adverse reactions of IFN.
In chronic hepatitis C patients, the prevalence of steatosis
ranges from 40% to 86% (mean, 55%) [41,  42]. The
majority of patients with steatosis (78%) have mild steatosis
affecting less than 30% of hepatocytes. Thus, steatosis
occurs more frequently in patients with chronic hepatitis C
(55%) than in the general population (20%–30%) of adults
in the Western world [43]. Hepatic steatosis in the patients
with chronic hepatitis C relates to host factors (alcohol
consumption, overweight, hyperlipidemia, diabetes, insulin
resistance) as well as viral factor (HCV genotype 3) [44].
Hepatic steatosis can exacerbate T cell mediated liver injury,
partly by polarizing T helper cells towards a TH-1 response
with excess production of interferon-gamma and interleulin-
2 [45,  46]. Furthermore, insulin resistance accompanied
with hepatic steatosis interferes with IFN signaling cascade
[71] through upregulation of SOCS-3, phosphoenolpyruvate
carboxy kinase and activation of phosphatidylinositol-3-
kinase (PI3K) that inhibit phosphorylation of STAT1 [47].
Hepatic steatosis are associated with enhanced lymphocyte
responsiveness to hepatic chemokines, resulting in increased
hepatic inflammatory cells [48]. Unfortunately, in recent
study, we had not examined presence of fatty liver in the
patients. In baseline characteristics, ALT in control group
tended to be higher than that in retinol group despite of
almost same viral load between both groups. It is possible
that the patients with fatty liver in control group were more
than that in retinol group. Further study involved host factors
is necessary in the future.
In conclusion, we suggest that retinol supplement increases
the antiviral effect of interferon α-2b plus ribavirin only
during the administration of IFN α-2b, ribavirin and retinol
in patients with chronic hepatitis C, and this mechanism may
mediate increase of IFN receptors. However this early
virological effect did not influence sustained virological
response. Further trial of continuous retinol administration
during the interferon plus ribavirin combination therapy is
necessary.
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